These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 35904917)

  • 1. [Successful treatment with risankizumab in a patient with psoriasis and HIV].
    Sanguinetti J; Suar L; Eimer L; Busso C
    Medicina (B Aires); 2022; 82(4):605-608. PubMed ID: 35904917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review.
    Bartos G; Cline A; Beroukhim K; Burrall BA; Feldman SR
    Dermatol Online J; 2018 Nov; 24(11):. PubMed ID: 30695971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
    Augustin M; Lambert J; Zema C; Thompson EHZ; Yang M; Wu EQ; Garcia-Horton V; Geng Z; Valdes JM; Joshi A; Gordon KB
    JAMA Dermatol; 2020 Dec; 156(12):1344-1353. PubMed ID: 33052382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
    Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
    N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.
    Strober B; Menter A; Leonardi C; Gordon K; Lambert J; Puig L; Photowala H; Longcore M; Zhan T; Foley P
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2830-2838. PubMed ID: 32320088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
    Li W; Ghamrawi R; Haidari W; Feldman SR
    Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
    [No Abstract]   [Full Text] [Related]  

  • 10. A drug safety evaluation of risankizumab for psoriasis.
    Huang YW; Tsai TF
    Expert Opin Drug Saf; 2020 Apr; 19(4):395-402. PubMed ID: 32100591
    [No Abstract]   [Full Text] [Related]  

  • 11. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
    Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
    Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.
    Blair HA
    Drugs; 2020 Aug; 80(12):1235-1245. PubMed ID: 32632826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
    Gooderham M; Pinter A; Ferris LK; Warren RB; Zhan T; Zeng J; Soliman AM; Kaufmann C; Kaplan B; Photowala H; Strober B
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):855-865. PubMed ID: 35174556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of psoriasis with risankizumab in an HIV positive patient with sexually transmitted infection comorbidities.
    Rob F; Rozsypal H
    Dermatol Ther; 2022 Mar; 35(3):e15277. PubMed ID: 34923721
    [No Abstract]   [Full Text] [Related]  

  • 16. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation.
    Menon K; Van Voorhees AS; Bebo BF; Gladman DD; Hsu S; Kalb RE; Lebwohl MG; Strober BE;
    J Am Acad Dermatol; 2010 Feb; 62(2):291-9. PubMed ID: 19646777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
    J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on risankizumab for the treatment of moderate to severe psoriasis.
    Al-Janabi A; Warren RB
    Expert Opin Biol Ther; 2020 Nov; 20(11):1245-1251. PubMed ID: 32933320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment.
    Yu Q; Ge X; Jing M; Mi X; Guo J; Xiao M; Lei Q; Chen M
    J Immunol Res; 2022; 2022():2802892. PubMed ID: 36033390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
    Warren RB; Blauvelt A; Poulin Y; Beeck S; Kelly M; Wu T; Geng Z; Paul C
    Br J Dermatol; 2021 Jan; 184(1):50-59. PubMed ID: 32594522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.